The EV-302 clinical trial revealed impressive efficacy of enfortumab vedotin and pembrolizumab (EV/P) combination therapy, with substantial improvements in overall survival (OS) and progression-free survival (PFS) in comparison to standard chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Benefits observed with EV/P were consistent across various patient subgroups. Nevertheless, the toxicity profile and patient comorbidities need to be taken into account when considering this therapeutic combination. The compatibility of EV with various agents suggests a promising future in the treatment of UC, and ongoing research into biomarkers and resistance mechanisms will further refine its application.
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer / Catalano, Martina; Santoni, Matteo; Roviello, Giandomenico. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - ELETTRONICO. - (2024), pp. 1-1. [10.1016/j.eururo.2024.05.001]
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Catalano, Martina;Roviello, Giandomenico
2024
Abstract
The EV-302 clinical trial revealed impressive efficacy of enfortumab vedotin and pembrolizumab (EV/P) combination therapy, with substantial improvements in overall survival (OS) and progression-free survival (PFS) in comparison to standard chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Benefits observed with EV/P were consistent across various patient subgroups. Nevertheless, the toxicity profile and patient comorbidities need to be taken into account when considering this therapeutic combination. The compatibility of EV with various agents suggests a promising future in the treatment of UC, and ongoing research into biomarkers and resistance mechanisms will further refine its application.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
